Switch theme
Sign up to access all valuation multiples
Indegene Ltd provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. Its portfolio of solutions covers all aspects of commercial, medical, regulatory, and R&D operations of life sciences companies. The company segment includes Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation, and Others. Key revenue is generated from the Omnichannel Activation segment.
1998
5.2K+
LTM Revenue $339M
LTM EBITDA $65.1M
$1.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Indegene has a last 12-month revenue (LTM) of $339M and a last 12-month EBITDA of $65.1M.
In the most recent fiscal year, Indegene achieved revenue of $333M and an EBITDA of $75.1M.
Indegene expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Indegene valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $339M | XXX | $333M | XXX | XXX | XXX |
| Gross Profit | $114M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 34% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | $65.1M | XXX | $75.1M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $55.6M | XXX | $53.2M | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $49.2M | XXX | $47.6M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 14% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Indegene's stock price is INR 601 (or $7).
Indegene has current market cap of INR 144B (or $1.7B), and EV of INR 128B (or $1.5B).
See Indegene trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.5B | $1.7B | XXX | XXX | XXX | XXX | $0.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Indegene has market cap of $1.7B and EV of $1.5B.
Indegene's trades at 4.6x EV/Revenue multiple, and 20.5x EV/EBITDA.
Equity research analysts estimate Indegene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Indegene has a P/E ratio of 34.3x.
See valuation multiples for Indegene and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.7B | XXX | $1.7B | XXX | XXX | XXX |
| EV (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV/Revenue | 4.4x | XXX | 4.6x | XXX | XXX | XXX |
| EV/EBITDA | 23.1x | XXX | 20.5x | XXX | XXX | XXX |
| EV/EBIT | 27.0x | XXX | 28.7x | XXX | XXX | XXX |
| EV/Gross Profit | 13.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 34.3x | XXX | 37.0x | XXX | XXX | XXX |
| EV/FCF | 33.1x | XXX | 29.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIndegene's last 12 month revenue growth is 12%
Indegene's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Indegene's rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Indegene's rule of X is 49% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Indegene and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | 4% | XXX | XXX | XXX |
| Rule of 40 | 34% | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 49% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 84% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Alcidion Group | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Doctor Care Anywhere | XXX | XXX | XXX | XXX | XXX | XXX |
| Echo IQ | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Indegene acquired XXX companies to date.
Last acquisition by Indegene was XXXXXXXX, XXXXX XXXXX XXXXXX . Indegene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Indegene founded? | Indegene was founded in 1998. |
| Where is Indegene headquartered? | Indegene is headquartered in India. |
| How many employees does Indegene have? | As of today, Indegene has 5.2K+ employees. |
| Who is the CEO of Indegene? | Indegene's CEO is Mr. Manish Gupta. |
| Is Indegene publicy listed? | Yes, Indegene is a public company listed on NSE. |
| What is the stock symbol of Indegene? | Indegene trades under INDGN ticker. |
| When did Indegene go public? | Indegene went public in 2024. |
| Who are competitors of Indegene? | Similar companies to Indegene include e.g. Benevolent AI, Alcidion Group, CurveBeam AI, Doctor Care Anywhere. |
| What is the current market cap of Indegene? | Indegene's current market cap is $1.7B |
| What is the current revenue of Indegene? | Indegene's last 12 months revenue is $339M. |
| What is the current revenue growth of Indegene? | Indegene revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Indegene? | Current revenue multiple of Indegene is 4.4x. |
| Is Indegene profitable? | Yes, Indegene is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Indegene? | Indegene's last 12 months EBITDA is $65.1M. |
| What is Indegene's EBITDA margin? | Indegene's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Indegene? | Current EBITDA multiple of Indegene is 23.1x. |
| What is the current FCF of Indegene? | Indegene's last 12 months FCF is $45.5M. |
| What is Indegene's FCF margin? | Indegene's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of Indegene? | Current FCF multiple of Indegene is 33.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
